Business
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance
About this update from Kamada Ltd.
[{"type":"text","content":"2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance is Based Solely on Continued Organic GrowthCompany Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million - $182 Million in Revenues and $40 Million - $44 Million of Adjusted EBITDA2025 Year-End Cash of Approximately $75 Million REHOVOT, Israel and HOBOKEN, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, based on its positive outlook for 2026, it is forecasting continued double-digit profitable growth with 2026 annual guidance of $200 million - $205 million in revenues and $50 million - $53 million of adjusted EBITDA. Importantly, the projected 2026 growth is based solely on continued organic growth of the Company’s diverse commercial products portfolio in multiple markets in both its Proprietary segment which covers the specialty plasma therapies and the Distribution segment which covers commercialization of in-licensing third parties biopharmaceutical products. The 2026 midpoint guidance range represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA, based on the mid-points of Kamada’s 2025 guidance. The Company further announced that it expects to achieve its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million of adjusted EBITDA, with 2025 year-end cash of approximately $75 million. Kamada intends to publish its 2025 financial results during the first half of March 2026. “We enter 2026 from a position of significant commercial and financial strength and are excited about the progress we have made over the past year,” said Amir London, Kamada’s Chief Executive Officer. “We look forward to achieving our value generating objectives for 2026, driven by continued organic growth of our diverse commercial product portfolio marketed in over 30 countries. We are also pleased with our ability to consistently convert adjusted EBITDA into operational cash.” “Our projected growth in 2026...